Related Experiment Video
Updated: Jun 29, 2025
A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules
Published on: March 10, 2017
High-Throughput Cell-Based Screening of Small Molecule KRAS Signaling Inhibitors Using a Homogeneous Time-Resolved
Brian P Smith1, Megan Rigby1, Roger Ma1
1NCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Abstract:
With recent advances proving that effective inhibition of KRAS is possible, there have been significant efforts made to develop inhibitors of specific mutant alleles. Here we describe a detailed protocol that employs homogeneous time-resolved fluorescence (HTRF) to identify compounds acting on KRAS signaling in malignant cell lines. This method allows for high-throughput, cell-based screens of large compound libraries for the development of RAS-targeted therapeutics.
Insights
Researchers developed a new HTRF method to screen for KRAS inhibitors in cancer cells. This high-throughput assay aids in discovering novel RAS-targeted therapeutics for cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Recent breakthroughs demonstrate the feasibility of inhibiting KRAS.
- Significant research is underway to develop inhibitors targeting specific KRAS mutations.
- KRAS signaling is a critical pathway in various malignancies.
Purpose of the Study:
- To present a detailed protocol for identifying compounds that modulate KRAS signaling.
- To enable high-throughput screening of compound libraries for KRAS-targeted drug discovery.
- To facilitate the development of novel therapeutics for KRAS-driven cancers.
Main Methods:
- Utilized homogeneous time-resolved fluorescence (HTRF) technology.
- Developed a cell-based screening assay for KRAS signaling.
- Applied the method to screen large compound libraries.
Main Results:
- Successfully established a robust HTRF-based protocol.
- Demonstrated the utility of the assay for identifying active compounds.
- Validated the method for screening in malignant cell lines.
Conclusions:
- The described HTRF protocol is effective for high-throughput screening of KRAS inhibitors.
- This method supports the development of targeted therapies for cancers with KRAS mutations.
- The assay is a valuable tool for advancing RAS-targeted therapeutic strategies.
